172 related articles for article (PubMed ID: 36057616)
1. Longitudinal change in ATN biomarkers in cognitively normal individuals.
Ebenau JL; Visser D; Kroeze LA; van Leeuwenstijn MSSA; van Harten AC; Windhorst AD; Golla SVS; Boellaard R; Scheltens P; Barkhof F; van Berckel BNM; van der Flier WM
Alzheimers Res Ther; 2022 Sep; 14(1):124. PubMed ID: 36057616
[TBL] [Abstract][Full Text] [Related]
2. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
3. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project.
Ebenau JL; Timmers T; Wesselman LMP; Verberk IMW; Verfaillie SCJ; Slot RER; van Harten AC; Teunissen CE; Barkhof F; van den Bosch KA; van Leeuwenstijn M; Tomassen J; Braber AD; Visser PJ; Prins ND; Sikkes SAM; Scheltens P; van Berckel BNM; van der Flier WM
Neurology; 2020 Jul; 95(1):e46-e58. PubMed ID: 32522798
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline.
Bucci M; Chiotis K; Nordberg A;
Mol Psychiatry; 2021 Oct; 26(10):5888-5898. PubMed ID: 34593971
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of imaging-based ATN profiles in a memory clinic cohort.
Peretti DE; Ribaldi F; Scheffler M; Chicherio C; Frisoni GB; Garibotto V
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3313-3323. PubMed ID: 37358619
[TBL] [Abstract][Full Text] [Related]
6. Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint.
Thomas KR; Weigand AJ; Edwards LC; Edmonds EC; Bangen KJ; Ortiz G; Walker KS; Bondi MW;
Alzheimers Res Ther; 2022 Aug; 14(1):114. PubMed ID: 35996158
[TBL] [Abstract][Full Text] [Related]
7. Exploring the ATN classification system using brain morphology.
Heinzinger N; Maass A; Berron D; Yakupov R; Peters O; Fiebach J; Villringer K; Preis L; Priller J; Spruth EJ; Altenstein S; Schneider A; Fliessbach K; Wiltfang J; Bartels C; Jessen F; Maier F; Glanz W; Buerger K; Janowitz D; Perneczky R; Rauchmann BS; Teipel S; Killimann I; Göerß D; Laske C; Munk MH; Spottke A; Roy N; Heneka MT; Brosseron F; Dobisch L; Ewers M; Dechent P; Haynes JD; Scheffler K; Wolfsgruber S; Kleineidam L; Schmid M; Berger M; Düzel E; Ziegler G;
Alzheimers Res Ther; 2023 Mar; 15(1):50. PubMed ID: 36915139
[TBL] [Abstract][Full Text] [Related]
8. Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer's disease polygenic risk score.
Tomassen J; den Braber A; van der Lee SJ; Reus LM; Konijnenberg E; Carter SF; Yaqub M; van Berckel BNM; Collij LE; Boomsma DI; de Geus EJC; Scheltens P; Herholz K; Tijms BM; Visser PJ
BMC Neurol; 2022 Dec; 22(1):484. PubMed ID: 36522743
[TBL] [Abstract][Full Text] [Related]
9. Applying the ATN scheme in a memory clinic population: The ABIDE project.
Altomare D; de Wilde A; Ossenkoppele R; Pelkmans W; Bouwman F; Groot C; van Maurik I; Zwan M; Yaqub M; Barkhof F; van Berckel BN; Teunissen CE; Frisoni GB; Scheltens P; van der Flier WM
Neurology; 2019 Oct; 93(17):e1635-e1646. PubMed ID: 31597710
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia.
Tan MS; Ji X; Li JQ; Xu W; Wang HF; Tan CC; Dong Q; Zuo CT; Tan L; Suckling J; Yu JT;
Alzheimers Res Ther; 2020 May; 12(1):55. PubMed ID: 32393375
[TBL] [Abstract][Full Text] [Related]
11. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
[TBL] [Abstract][Full Text] [Related]
12. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease diagnostic accuracy by fluid and neuroimaging ATN framework.
Xiong X; He H; Ye Q; Qian S; Zhou S; Feng F; Fang EF; Xie C
CNS Neurosci Ther; 2024 Feb; 30(2):e14357. PubMed ID: 37438991
[TBL] [Abstract][Full Text] [Related]
15. Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies.
van de Beek M; Ooms FAH; Ebenau JL; Barkhof F; Scheltens P; Teunissen CE; van Harten AC; van der Flier WM; Lemstra AW
Neurology; 2022 Mar; 98(12):e1262-e1272. PubMed ID: 35074893
[TBL] [Abstract][Full Text] [Related]
16. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia.
Jack CR; Wiste HJ; Therneau TM; Weigand SD; Knopman DS; Mielke MM; Lowe VJ; Vemuri P; Machulda MM; Schwarz CG; Gunter JL; Senjem ML; Graff-Radford J; Jones DT; Roberts RO; Rocca WA; Petersen RC
JAMA; 2019 Jun; 321(23):2316-2325. PubMed ID: 31211344
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease.
Delmotte K; Schaeverbeke J; Poesen K; Vandenberghe R
Alzheimers Res Ther; 2021 Apr; 13(1):84. PubMed ID: 33879243
[TBL] [Abstract][Full Text] [Related]
18. Baseline [
Teng E; Manser PT; Sanabria Bohorquez S; Wildsmith KR; Pickthorn K; Baker SL; Ward M; Kerchner GA; Weimer RM
Alzheimers Res Ther; 2021 Dec; 13(1):196. PubMed ID: 34852837
[TBL] [Abstract][Full Text] [Related]
19. Association of cortical microstructure with amyloid-β and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults.
Rodriguez-Vieitez E; Montal V; Sepulcre J; Lois C; Hanseeuw B; Vilaplana E; Schultz AP; Properzi MJ; Scott MR; Amariglio R; Papp KV; Marshall GA; Fortea J; Johnson KA; Sperling RA; Vannini P
Mol Psychiatry; 2021 Dec; 26(12):7813-7822. PubMed ID: 34588623
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
